Global Aptamers Market

According to the latest report by IMARC Group, titled “Aptamers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global aptamers market size reached US$ 4.3 Billion in 2020. Aptamers are single-stranded oligonucleotides that bind various molecules with high affinity and specificity. They are easy to prepare, versatile, highly sensitive, less toxic, and nonimmunogenic. As a result, they are employed in nanotechnology, nanoscience, and nanomedicine as molecular recognition elements. Besides this, as they offer high stability and scalability, aptamers are also utilized in rapid diagnostics, biosensors, and biotechnological applications across the globe.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Aptamers Market Trends:

There is currently a rise in the use of aptamers in biomarker and drug discovery as research agents, biosensors, and tools across the globe. This, along with the growing prevalence of severe diseases, such as cancer, acquired immunodeficiency syndrome (AIDS), and cardiovascular and neurodegenerative diseases, represents one of the key factors catalyzing the demand for effective assay techniques based on aptamer therapy. Moreover, aptamers are chemically synthesized antibodies that eliminate batch-to-batch variation and require less time for development. As they also have low molecular weight, they are extensively used in therapeutic and biotechnological applications. Furthermore, leading players are utilizing advanced procedures, such as the chemical modification process, to enhance the therapeutic properties and increase the nuclease resistance of aptamers. This, coupled with considerable investments in research and development (R&D) activities to improve diagnostic devices and drugs and their carriers, is acting as another growth-inducing factor. Looking forward, the market value is projected to reach US$ 12.9 Billion by 2026, expanding at a CAGR of 20% during the forecast period (2021-2026).

Market Summary:

• Based on the type, nucleic acid aptamers hold the largest market share, followed by peptide aptamers.
• On the basis of the application, the market has been segmented into diagnostics, therapeutics, research and development, and others. At present, there is an increase in the utilization of aptamers for diagnostics purposes.
• Region-wise, the market has been divided into North America (the United States and Canada); Asia Pacific (Australia, South Korea, China, India, Japan, Indonesia, and others); Europe (the United Kingdom, Spain, Italy, Germany, France, Russia, and others); Latin America (Mexico, Brazil, and others); and Middle East and Africa. Amongst these, North America enjoys the leading position in the market.
• The competitive landscape of the market has been examined, with some of the key players being Aptagen LLC, The Aptamer Group Ltd., Aptamer Sciences Inc., Aptatargets SL, Base Pair Biotechnologies, Inc., IBA Lifesciences GmbH, Kaneka Corporation, NeoVentures Biotechnology Inc., Noxxon Pharma, SomaLogic, Inc., TriLink Bio Technologies, LLC, and Vivonics Inc.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800